Adaptive Biotechnologies Corp (NASDAQ:ADPT) has a beta value of 1.80 and has seen 1.84 million shares traded in the recent trading session. The company, currently valued at $1.70B, closed the recent trade at $11.22 per share which meant it gained $0.57 on the day or 5.35% during that session. The ADPT stock price is 3.12% off its 52-week high price of $10.87 and 70.94% above the 52-week low of $3.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.43 million shares traded. The 3-month trading volume is 2.09 million shares.
The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is Hold stock at the moment, with a recommendation rating of 1.25. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 11 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Sporting 5.35% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADPT stock price touched $11.22 or saw a rise of 2.18%. Year-to-date, Adaptive Biotechnologies Corp shares have moved 246.28%, while the 5-day performance has seen it change 10.65%. Over the past 30 days, the shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) have changed 25.64%. Short interest in the company has seen 9.64 million shares shorted with days to cover at 3.87.
Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 19.86% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $18.0. In that case, then, we find that the latest price level in today’s session is -60.43% off the targeted high while a plunge would see the stock lose 55.44% from the levels at last check today..
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
The company’s shares have gained 86.99% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.51% over the past 5 years. Earnings growth for 2025 is a modest 21.47% while over the next 5 years, the company’s earnings are expected to increase by 30.19%.
ADPT Dividends
Adaptive Biotechnologies Corp is expected to release its next earnings report on 2025-May-01 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Insiders own 2.35% of the company shares, while shares held by institutions stand at 97.70% with a share float percentage of 100.05%. Investors are also buoyed by the number of investors in a company, with Adaptive Biotechnologies Corp having a total of 310.0 institutions that hold shares in the company. The top two institutional holders are VIKING GLOBAL INVESTORS LP with over 29.99 million shares worth more than $108.58 million. As of 2024-06-30, VIKING GLOBAL INVESTORS LP held 20.3466% of shares outstanding.
The other major institutional holder is RUBRIC CAPITAL MANAGEMENT LP, with the holding of over 14.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $50.68 million and represent 9.4971% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and ARK ETF Trust-ARK Genomic Revolution ETF . As of Mar 31, 2025 , the former fund manager holds about 2.95% shares in the company for having 4.49 shares of worth $50.61 million while later fund manager owns 4.32 shares of worth $48.69 million as of May 31, 2025 , which makes it owner of about 2.84% of company’s outstanding stock.
